Pancreatic cancer and FOLFIRINOX: a new era and new questions

Robert De W Marsh, Mark S Talamonti, Matthew Harold Katz, Joseph M Herman, Robert De W Marsh, Mark S Talamonti, Matthew Harold Katz, Joseph M Herman

Abstract

FOLFIRINOX (FFX) was introduced to clinical practice in 2010 following publication of the PRODIGE 4/ACCORD 11 study, which compared this novel regimen to gemcitabine in metastatic pancreatic cancer. Median overall survival, progression-free survival, and objective responses were all superior with FFX and there was improved time to definitive deterioration in quality of life. Despite initial concerns over toxicity, there has been rapid uptake of this regimen, both revolutionizing management and opening the door to innovative research. As experience with FFX has accrued, many questions have arisen including the management of toxicities, the impact of frequent modifications, the optimal number of cycles, integration with other regimens and modalities, interpretation of radiologic and serologic response, utility of molecular signatures, and potential benefit in unique clinical settings such as pre- and postsurgery. This review will closely examine these issues, not only to summarize current knowledge but also to fuel scientific debate.

Keywords: Chemotherapy; FOLFIRINOX; genomics; modifications; pancreatic cancer; toxicity.

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

References

    1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007;25:1960–1966.
    1. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009;27:5513–5518.
    1. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother. Pharmacol. 2008;61:167–175.
    1. Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, et al. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother. Pharmacol. 2012;69:425–430.
    1. Ychou M, Desseigne F, Guimbaud R, Ducreux M, Bouche O, Becouarn Y, et al. Randomized phase II trial comparing FOLFIRINOX (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. ASCO Meeting Abstr. 2007;25(Suppl. 18):4516.
    1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817–1825.
    1. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 2013;31:23–29.
    1. Bendell J, Britton S, Green M, Willey J, Lemke K, Marshall J. Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer. J. Clin. Oncol. 2011;29:2011. (suppl 4; abstr 286)
    1. Donahue TR, Kazanjian KK, Isacoff WH, Reber HA. Hines OJ. Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer. J. Gastrointest. Surg. 2010;14:1012–1018.
    1. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J. Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer. 2008;112:2283–2288.
    1. Wang HY, Shih SC, Lin SC, Chang WS, Wang TE, Lin FJ, et al. Partial splenic embolization: 12-month hematological effects and complications. Hepatogastroenterology. 2008;55:1838–1842.
    1. Gammon D, Bhargava P. McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist. 2004;9:546–549.
    1. Dodds HM, Bishop JF. Rivory LP. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J. Natl. Cancer Inst. 1999;91:91–92.
    1. Krexner E, Stickler A, Prainer C. Finsterer J. Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion. Med. Oncol. 2012;29:3592–3593.
    1. De Marco S, Squilloni E, Vigna L, Bertagnolio MF. Sternberg CN. Irinotecan chemotherapy associated with transient dysarthria and aphasia. Ann. Oncol. 2004;15:1147–1148.
    1. Basso M, Cassano A, Modoni A, Spada D, Trigila N, Quirino M, et al. A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur. J. Clin. Pharmacol. 2008;64:739–741.
    1. Amireault C, Beaudet J, Gaudet G, Raymond N, Ayoub J-P, Letourneau R, et al. FOLFIRINOX in the real-world setting: the multicentric experience of six Canadian institutions. ASCO Meeting Abstr. 2014;32(Suppl. 3):367.
    1. Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–1315.
    1. De Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur. J. Cancer Clin. Oncol. 1988;24:1499–1503.
    1. Tamura T, Kuwahara A, Kadoyama K, Yamamori M, Nishiguchi K, Inokuma T, et al. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. Int. J. Med. Sci. 2011;8:406–412.
    1. Sobrero AF, Aschele C. Bertino JR. Fluorouracil in colorectal cancer—a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 1997;15:368–381.
    1. James ES, Yao X, Cong X, Stein S, Kaley K, Hahn C, et al. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC) ASCO Meeting Abstr. 2014;32(Suppl. 3):256.
    1. Leichman CG, Leichman L, Spears CP, Rosen PJ, Muggia F, Jeffers S, et al. Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal cancers. Cancer Chemother. Pharmacol. 1990;26:57–61.
    1. Blazer MA, Wu CS-Y, Goldberg RM, Phillips GS, Schmidt CR, Muscarella P, et al. Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC) ASCO Meeting Abstr. 2014;32(Suppl. 3):275.
    1. Gunturu KS, Thumar JR, Hochster HS, Stein S, Yao X, Cong X, et al. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC) ASCO Meeting Abstr. 2012;30(Suppl. 4):330.
    1. Alessandretti MB, P Brandao E, Abrahao CM, Lino AR, Junior RM, Costa MA, et al. Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma. ASCO Meeting Abstr. 2013;31(Suppl. 15):e15176.
    1. Metges JP, Ramee JF, Douillard J-Y, Boucher E, Faroux R, Guerin-Meyer V, et al. Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer. ASCO Meeting Abstr. 2014;32(Suppl. 3):305.
    1. Innocenti F, Schilsky RL, Ramirez J, Janisch L, Undevia S, House LK, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J. Clin. Oncol. 2014;32:2328–2334.
    1. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.
    1. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szyminifka J, Huynh MA, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–548.
    1. Morris-Stiff G, Tan YM. Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur. J. Surg. Oncol. 2008;34:609–614.
    1. Nomura R, Ishizaki Y, Suzuki K. Kawasaki S. Development of hepatic steatosis after pancreatoduodenectomy. AJR Am. J. Roentgenol. 2007;189:1484–1488.
    1. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN. Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br. J. Surg. 2007;94:274–286.
    1. Samuel N. Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2012;9:77–87.
    1. Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, et al. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am. J. Clin. Oncol. 2007;30:15–20.
    1. Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artu P, et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann. Oncol. 2007;18:498–503.
    1. Son CO, Pai SG, Satti S, Dornelles A, Bolton JS, Conway WC, et al. Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Single-institution experience. ASCO Meeting Abstr. 2014;32(Suppl. 3):327.
    1. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
    1. Sultana A, Cox T, Ghaneh P. Neoptolemos JP. Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res. 2012;196:65–88.
    1. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J. Gastrointest. Surg. 2013;17:94–100. discussion p 00–1.
    1. Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen J, Gaudernack G, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int. J. Cancer. 2011;128:1120–1128.
    1. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA. Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362–375.
    1. Tuveson DA. Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148:21–23.
    1. Sohal DP, Walsh RM, Ramanathan RK. Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J. Natl. Cancer Inst. 2014;106:dju011.
    1. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 2008;26:3496–3502.
    1. MacKenzie S, Zeh H, McCahill LE, Sielaff TD, Bahary N, Gribben TE, et al. A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC) ASCO Meeting Abstr. 2013;31(Suppl. 15):4038.
    1. Alvarez-Gallego R, Cubillo A, Rodriguez-Pascual J, Quijano Y, De Vicente E, Garcia L, et al. Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. ASCO Meeting Abstr. 2012;30(Suppl. 15):4040.
    1. Minter RM, Feng MU-S, Al-Hawary M, Shen J, Schipper MJ, Bednar F, et al. Effect of neoadjuvant chemoradiotherapy (nCRT) on survival in patients with borderline resectable (BR) pancreatic adenocarcinoma (PDA) with acceptable peri-operative morbidity. ASCO Meeting Abstr. 2014;32(Suppl. 3):288.
    1. McCormick K, Whiting SH, Gyurkey G, Koh W-J, Sinanan M. L Coveler A. Long-term survival of patients receiving multimodality neoadjuvant therapy for resectable or borderline resectable pancreatic ductal adenocarcinoma. ASCO Meeting Abstr. 2014;32(Suppl. 3):309.
    1. Gulati AP, Schreibman SM, Schrope B, Lee JA, Allendorf J, Chabot JA, et al. Prospective phase II study of inoperable pancreatic adenocarcinoma with neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) ASCO Meeting Abstr. 2014;32(Suppl. 3):274.
    1. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266–274.
    1. Tian F, Appert HE, Myles J. Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann. Surg. 1992;215:350–355.
    1. Haglund C, Kuusela P. Roberts PJ. Tumour markers in pancreatic cancer. Ann. Chir. Gynaecol. 1989;78:41–53.
    1. Benhamou PY, Vuillez JP, Halimi S, Meffre G. Bachelot I. Influence of metabolic disturbances of diabetes mellitus on serum CA 19-9 tumor marker. Diabete Metab. 1991;17:39–43.
    1. Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dorken B, et al. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front. Oncol. 2013;3:155.
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013;369:1691–1703.
    1. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132–138.
    1. Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, et al. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch. Surg. 2011;146:836–843.
    1. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749–5756.
    1. Dholakia H-P. Wild R. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships. J. Radiat. Oncol. 2013;2:413–425.
    1. Zhao Q, Rashid A, Gong Y. Katz M. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann. Diagn. Pathol. 2012;16:29–37.
    1. Chun YSCH, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann. Surg. Oncol. 2011;18:3601–3607.
    1. De Angelis C, Brizzi RF. Pellicano R. Endoscopic ultrasonography for pancreatic cancer: current and future perspectives. J. Gastrointest. Oncol. 2013;4:220–230.
    1. Lu N, Feng XY, Hao SJ, Liang ZH, Jin C, Qiang JW, et al. 64-slice CT perfusion imaging of pancreatic adenocarcinoma and mass-forming chronic pancreatitis. Acad. Radiol. 2011;18:81–88.
    1. Epelbaum R, Israel O, Haddad R, Sikorski N. Frenkel A. Dynamic FDG-PET/CT as an indicator of tumor aggressiveness and patient outcome in pancreatic cancer. ASCO Meeting Abstr. 2010;28(Suppl. 15):e14526.
    1. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J. Clin. Invest. 2014;124:1525–1536.
    1. Hammel P, Huguet F, Van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. ASCO Meeting Abstr. 2013;31(Suppl. 15):LBA4003.
    1. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int. J. Radiat. Oncol. Biol. Phys. 2013;86:516–522.
    1. Chang ST, Goodman KA, Yang GP. Koong AC. Stereotactic body radiotherapy for unresectable pancreatic cancer. Front. Radiat. Ther. Oncol. 2007;40:386–394.
    1. Ramanathan RK, Lee P, Seng JE, Anthony SP, Rosen PJ, Mena RR, et al. Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer. ASCO Meeting Abstr. 2014;32(Suppl. 3):224.
    1. Hartlapp I, Muller J, Kenn W, Steger U, Isbert C, Schuerlen M, et al. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. Onkologie. 2013;36:123–125.
    1. Zhang Y, Hochster HS, Stein S. Lacy J. Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. ASCO Meeting Abstr. 2014;32(Suppl. 3):344.
    1. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, et al. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res. 2013;73:3235–3247.
    1. Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol. Ther. 2011;12:165–168.
    1. Leung K. Saif MW. BRCA-associated pancreatic cancer: the evolving management. J. Pancreas. 2013;14:149–151.
    1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
    1. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res. 2005;11:6100–6102.
    1. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin. Cancer Res. 2003;9:4165–4171.
    1. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 2004;10:6956–6961.
    1. Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J. Clin. Oncol. 2013;31:4453–4461.
    1. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study. ASCO Meeting Abstr. 2009;27:4525.
    1. Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann. Oncol. 2014;25:1025–1032.
    1. Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J. Gastrointest. Surg. 2011;15:1611–1617.
    1. Dunschede F, Will L, von Langsdorf C, Mohler M, Galle PR, Otto G, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur. Surg. Res. 2010;44:209–213.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa